Clinical Trials Logo
  1. Home
  2. Non-segmental Vitiligo
  3. NCT04942860

The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo — EVRAM  

Non-segmental Vitiligo Clinical Trial

Official title:
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo

Clinical Trial Summary

The aim of this study is to evaluate the influence of two concentrations of methotrexate on vitiligous lesions in patients with non-segmental vitiligo

Clinical Trial Description

Methotrexate, synthesized in the 1950s as an anticancer drug with an antiproliferative effect, is currently one of the most commonly used immunosuppressive agents in dermatology. The use of small, non-oncological doses has revealed its anti-inflammatory properties, including the impact on a number of cytokines involved in the pathogenesis of autoimmune diseases. It has been shown that treatment with methotrexate reduces the levels of TNF-alpha-producing T cells, while the number of IL-10 producing T cells increases. Methotrexate also inhibits the synthesis of interferon-γ. The above considerations justify the use of topical methotrexate in patients with vitiligo in order to obtain repigmentation. A study has been designed as a single-center, randomized, double-blind, placebo-controlled pilot study with the enrollment of up to 100 active non-segmental vitiligo patients presenting with vitiligous lesions on both upper and lower limbs. Clinical effects of gel containing 1% methotrexate or 0.5% methotrexate applied on a preselected limb will be assessed in comparison with vehicle ointment applied on the opposite limb. All study participants will undergo clinical evaluation using Body Surface Area (BSA) and Vitiligo Area Scoring Index (VASI) scales at baseline, week 4, week 8 and week 12 time points. Precise assessment of skin lesions will be performed using photographic documentation obtained during each study visit and processed with NIS-Elements software. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04942860
Study type Interventional
Source Nicolaus Copernicus University
Contact
Status Completed
Phase Phase 3
Start date October 1, 2019
Completion date August 31, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04052425 - Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) Phase 3
Completed NCT04057573 - Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Phase 3
Recruiting NCT06113328 - A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) Phase 2
Recruiting NCT01377077 - Punchgrafting Techniques for Vitiligo Phase 4
Completed NCT04927975 - Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Phase 2
Completed NCT04487860 - Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo Phase 2
Active, not recruiting NCT04811326 - Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation Phase 4
Terminated NCT03022019 - ReNovaCell in Non-segmental Vitiligo N/A
Completed NCT03247400 - The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo Phase 1/Phase 2
Not yet recruiting NCT05990309 - ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO N/A